Whole-body bone scintigraphy (BS) with 99mTc-MDP has the highest cost-benefit ratio for bone metastasis (BM) diagnosis on breast cancer (BC) patients. However, BS frequently shows inconclusive findings, making necessary the use of complementary exams.This study aimed to compare 18F-Fluoride-PET/CT and 18F-FDG-PET/CT for the diagnosis of BM on BC patients with inconclusive BS for BM.
Introduction
Bone is one of the most regular site for metastasis on various carcinomas, being specially common on breast cancer (BC). The early detection of bone metastasis (BM) plays a major role on delivering the appropriate treatment for the patient.
Whole-body bone scintigraphy (BS) with 99m Tc-MDP is the conventional test to find BM, due to its high costbenefit ratio; however, BS frequently shows inconclusive findings, making necessary the use of complementary exams.
This study compared 18 F-Fluoride-PET/CT and 18 F-FDG-PET/CT for the diagnosis of BM on BC patients with inconclusive BS.
Results and Discussion
18 patients participated on this study. The inclusion criteria was: sign the informed consent document, show a BS with inconclusive findings for BM, been undiagnosed for BM and accept the realization of 18 
Conclusions
On the present study, 18 F-Fluoride-PET/CT was considered the best complementary exam to diagnose BM on patients with inconclusive BS findings. 18 F-Fluoride-PET/CT had a higher sensitivity for sclerotic and mixed lesions, an equal sensitivity for lytic lesions and inferior sensitivity for early stage lesions. Interestingly, 18 F-FDG-PET/CT detected a large amount of early stage lesions in a single patient; rising significantly his sensitivity for this kind of BM. ____________________ 
